Given the frequent coexistence of hypertension, heart failure, and type 2 diabetes in patients with CKD, the addition of SGLT-2 inhibitors offers a multifaceted therapeutic strategy that includes modest blood pressure-lowering effects (86). Here, SLC5A2 is linked to hypertensive disorder.